All In Biotech

Drug Trial Radar · NCT07007962

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 24, 2025

Primary completion

Nov 5, 2027

Study completion Dec 30, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.

Conditions

  • Immune Thrombocytopenia

Interventions

  • rilzabrutinibDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Durable platelet responseTime frame: Until Week 28

Locations

54 sites in 10 countries. Site status is shown where the registry gives one.

  • Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) Site Number: 8400005

    Clovis, California · Recruiting

  • University of Southern California (USC) Norris Comprehensive Cancer Center Site Number: 8400015

    Los Angeles, California · Recruiting

  • The Lundquist Institute for Biomedical Innovation - Harbor-UCLA Medical Center Site Number: 8400017

    Torrance, California · Recruiting

  • MedStar Georgetown University Hospital Site Number: 8400014

    Washington D.C., District of Columbia · Recruiting

  • Bleeding and Clotting Disorders Institute Site Number: 8400018

    Peoria, Illinois · Recruiting

  • Tulane University Health Sciences Center - Tulane Avenue-Investigational Site Number: 8400011

    New Orleans, Louisiana · Recruiting

  • Massachusetts General Hospital Site Number: 8400004

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center Site Number: 8400019

    Boston, Massachusetts · Recruiting

  • Mass General/North Shore Cancer Center Site Number: 8400020

    Danvers, Massachusetts · Recruiting

  • University of Michigan Health - Michigan Medicine - University Hospital Site Number: 8400001

    Ann Arbor, Michigan · Recruiting

  • M Health Center for Bleeding and Clotting Disorders Site Number: 8400013

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic_Investigational Site Number: 8400009

    Rochester, Minnesota · Recruiting

  • New York Oncology Hematology Site Number: 8400010

    Albany, New York · Recruiting

  • Montefiore Medical Center-Investigational Site Number: 8400012

    The Bronx, New York · Recruiting

  • Oregon Health & Science University - Knight Cancer Institute Site Number: 8400006

    Portland, Oregon · Recruiting

  • East Carolina University Site Number: 8400003

    Greenville, South Carolina · Recruiting

  • Community Cancer Trials of Utah Site Number: 8400002

    Ogden, Utah · Recruiting

  • University of Washington Site Number: 8400008

    Seattle, Washington · Recruiting

  • Investigational Site Number : 0400001

    Hanusch-Krankenhaus, Austria · Recruiting

  • Investigational Site Number : 2030001

    Ostrava, Czechia · Recruiting

  • Investigational Site Number : 2030002

    Prague, Czechia · Recruiting

  • Investigational Site Number : 2500005

    Antony, France · Recruiting

  • Investigational Site Number : 2500003

    Créteil, France · Recruiting

  • Investigational Site Number : 2500001

    Dijon, France · Recruiting

  • Investigational Site Number : 2500002

    Pessac, France · Recruiting

  • Investigational Site Number : 2500004

    Toulouse, France · Recruiting

  • Investigational Site Number : 2760005

    Berlin, Germany · Recruiting

  • Investigational Site Number : 2760001

    Dresden, Germany · Recruiting

  • Investigational Site Number : 2760006

    Essen, Germany · Recruiting

  • Investigational Site Number : 2760002

    Frankfurt am Main, Germany · Recruiting

  • Investigational Site Number : 2760004

    Leipzig, Germany · Recruiting

  • Investigational Site Number : 3480001

    Budapest, Hungary · Recruiting

  • Investigational Site Number : 3480003

    Debrecen, Hungary · Recruiting

  • Investigational Site Number : 3480002

    Kaposvár, Hungary · Recruiting

  • Investigational Site Number : 3800002

    Meldola, Italy · Recruiting

  • Investigational Site Number : 3800004

    Milan, Italy · Recruiting

  • Investigational Site Number : 3800006

    Naples, Italy · Recruiting

  • Investigational Site Number : 3800007

    Torino, Italy · Recruiting

  • Investigational Site Number : 3800001

    Trieste, Italy · Recruiting

  • Investigational Site Number : 3800003

    Vicenza, Italy · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.